A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer

Clinical Trial Details

This clinical trial is designed for men and women with stage 4 squamous and non-squamous (NSCLC) who have not received prior systemic therapy for the advanced disease.

The purpose of this study is to evaluate the safety and tolerability of EIK1001 with pembrolizumab and chemotherapy in participants with histologically confirmed Stage 4 non-squamous or squamous NSCLC.

EIK1001 is experimental, which means that it is being tested and is not yet approved by the United States Food and Drug Administration (FDA).

In this study, EIK1001 will be given to all participants intravenously (meaning through a needle in the vein directly into the blood).

Participation is expected to last up to 30 months. During that time, participants will have visits weekly for approximately 6 months and then once every three weeks going forward.

Key Eligibility:

Open to men and women above the age of 18 who have been confirmed Stage 4 NSCLC (predominantly squamous or non-squamous) and are considered a candidate for standard therapy with pembrolizumab and chemotherapy.
Participants must not currently be participating in or has participated in a study of an investigational agent and received investigational therapy within 4 weeks of administration of EIK1001.

Detailed eligibility will be reviewed when you contact the study team.

Return to List

Study contact by location

Upper East Side - Manhattan

Contact(s)

Natalie Agudo, RN
646-962-5060
naa9101@med.cornell.edu

Primary Investigator(s)

Ashish Saxena, MD, PhD

Protocol ID(s)

Weill Cornell Medicine IRB #:

2411028142

ClinicalTrials.gov:

NCT06246110

Status

Open to Enrollment

Age Group

Adult

Disease

Lung Cancer

Non-Small Cell Lung Cancer